戻る

HUTCHMED submits US NDA for ORPATHYS and TAGRISSO lung cancer combination

  • HUTCHMED submitted a US NDA for ORPATHYS® plus TAGRISSO®.
  • The application concerns MET-driven, EGFR-mutated lung cancer.
  • The filing seeks US regulatory consideration of the treatment combination.

HUTCHMED announced the submission of a U.S. New Drug Application (NDA) for ORPATHYS® plus TAGRISSO® in MET-driven, EGFR-mutated lung cancer. The filing seeks U.S. regulatory consideration of the two-drug combination for this defined form of lung cancer.

当サイトの情報はAIを用いて生成されており、正確性を保証するものではありません。 参考情報としてご活用ください。